Differences between indirect comparison studies of the oral anticoagulants for stroke prevention in atrial fibrillation: Where do we go next?

QJM: An International Journal of Medicine

Volumn 106, Issue 1, 2013, Pages 95-96

  Harenberg, Job ^a   Lip, Gregory Y H ^b  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; MORTALITY; PRIORITY JOURNAL;

EID: 84871531337     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs224     Document Type: Letter

References (5)

1. Testa L, Agnifili M, Latini RA, Mattioli R, Lanotte S, De Marco F, et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 2012; 105:949-57.
2. Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 2012; 35:330-9.
3. Wells GA, Coyle D, Cameron C, Steiner S, Coyle K, Kelly S, et al. Safety, Effectiveness, and Cost-effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. http://www.cadth.ca/media/pdf/NOAC_Therapeutic_Review_final_report.pdf (4 July 2012, date last assessed).
4. Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012; 60:738-46.
5. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108:476-84.